Iliana Lanz

Iliana Lanz is an Associate Scientist at Amgen since March 2024, previously serving as an Associate Research Scientist and Research Technician at AbCellera from August 2019 to December 2023. Iliana led a team of up to 10 scientists in developing cloning strategies to enhance antibody expression, contributing to the clinical antibody treatment Bebtelovimab and a related publication. Earlier experience includes a Student Researcher position at BC Cancer, where an honours thesis focused on triple-negative breast cancer and mitophagy, a Protein Engineering Co-op at Zymeworks Inc., where protein expression and purification techniques were applied, and a Drug Delivery and Formulation Co-op at adMare BioInnovations, contributing to medical device formulation. Iliana holds a Bachelor of Science with Honours and Distinction in Molecular Biology and Biochemistry from Simon Fraser University and completed a writing course from Stanford Online.